United States

Alembic Pharmaceuticals has secured final approval from the US Food and Drug Administration for its generic version of levothyroxine sodium tablets, a widely prescribed treatment for hypothyroidism. The approval covers multiple dosage strengths and positions the company to expand its footprint in the highly competitive US generics market. The medication is therapeutically equivalent to Synthroid, a leading thyroid replacement therapy marketed by AbbVie.

Lupin Ltd has reached a settlement agreement worth USD 30 million (approximately Rs 250 crore) through its U.S. subsidiary Lupin Pharmaceuticals Inc with Humana Inc, resolving allegations tied to anti-competitive practices. The dispute was part of a broader, consolidated litigation framework in the United States involving multiple pharmaceutical firms. The settlement allows Lupin to mitigate legal uncertainties and refocus on its core business operations, while avoiding prolonged litigation risks in a complex regulatory environment.

Resolution of a Complex Legal Dispute

Aurobindo Pharma has received final approval from the US Food and Drug Administration to manufacture and market a generic version of glycerol phenylbutyrate oral liquid, a treatment for urea cycle disorders. The product, with a strength of 1.1 gram per ml, is therapeutically equivalent to the branded drug Ravicti. With an estimated market size of USD 50.2 million (approximately Rs 420 crore), the approval marks a strategic addition to Aurobindo’s U.S. portfolio, reinforcing its position in niche and specialty therapeutic segments.

Regulatory Milestone Enhances Product Pipeline

Precious metals markets are poised for heightened volatility following the collapse of diplomatic negotiations between the United States and Iran, a development that has unsettled global investor sentiment. Analysts expect gold and silver prices to react sharply as geopolitical risks intensify and macroeconomic indicators come into focus. Key triggers include inflation data, crude oil price movements, and signals from central banks, particularly the US Federal Reserve. In India, trading schedules will also be briefly disrupted due to a public holiday.

Global financial markets are bracing for heightened volatility as diplomatic talks between the United States and Iran concluded without a breakthrough, intensifying geopolitical uncertainty. Analysts expect investor sentiment to remain fragile when trading resumes, with crude oil prices emerging as a critical variable influencing market direction. The failure to reach a consensus has raised concerns over prolonged tensions in West Asia, a region central to global energy supply chains.

India and the United States have taken a significant step toward achieving their ambitious USD 500 billion bilateral trade target with the launch of the India-US Trade Facilitation Portal. Unveiled by Foreign Secretary Vikram Misri during his three-day US visit, the portal aims to streamline trade processes, reinforce existing supply chains, and foster new commercial linkages.

XRP faced renewed selling pressure as escalating geopolitical tensions between the United States and Iran dampened investor sentiment across global financial markets. After briefly gaining momentum, the cryptocurrency retreated over 3.5 percent from its weekly high, reflecting broader risk-off behavior seen in equities and digital assets. Conflicting signals around potential diplomatic engagement further fueled volatility, triggering significant liquidations in XRP futures markets.

A significant tightening of US immigration policies in 2025 has led to a notable decline in visa approvals, with India and China bearing the brunt of the reduction. Data indicates that approximately 2.5 lakh fewer visas were issued in the first eight months of the year compared to the same period in 2024. The decline, driven largely by reduced approvals for students and skilled workers, signals a shift in US immigration priorities.